⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 1, 2026

Soluble Fas Ligand, an overlooked target of therapy in dermatological and non-dermatological conditions.

Roberta Lotti Brydon Bennett Alessandra Marconi Antonino Amato Carlo Pincelli

View Full Paper

Ask AI

Bookmark

Share

Key Points

To explore the therapeutic potential of blocking soluble Fas ligand in various diseases.
Identified diseases influenced by soluble Fas ligand
Analyzed the effects of blocking techniques
Reviewed existing therapies and their limitations
Blocking soluble Fas ligand shows promise in altering disease progression
Potential therapeutic applications extend to both dermatological and non-dermatological conditions

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

This research evaluates the potential of blocking soluble Fas ligand to modify disease outcomes, suggesting its therapeutic value across conditions.

Abstract

By selectively blocking sFasL, one could potentially modify the course of several diseases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lotti et al. (2026) studied this question.

synapsesocial.com/papers/69a7cdf0d48f933b5eeda51b https://doi.org/10.1080/09546634.2026.2635884

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Fas Death FactorOriginal Research · 1995 · 3,981 citations
2Synthesis of N‐Glycosylated Soluble Fas Ligand2024
3Fas and Fas ligand in gut and liverReview · 2000 · 4 citations
4Soluble Fas Ligand Is Chemotactic for Human Neutrophilic Polymorphonuclear LeukocytesOriginal Research · 1999 · 179 citations
5Mechano-inhibition of endocytosis sensitizes cancer cells to Fas-induced Apoptosis2024 · 15 citations